7 mg of study medication daily throughout the period. The compliance with study medication (rhGH and placebo) was 99% in the GH group and 98% in the placebo group. No malignancies, changes in viral load or significant changes in total CD4 cell count occurred. Arthralgias were more frequent in the GH group (51% in the GH group and 17% in the placebo group; P=0.02). Results for fat distribution are shown in Table 2 and

Fig. 2. The GH group showed a significant reduction in VAT and trunk fat mass from baseline to week 40, compared with the placebo group. The median change in VAT was −18.9 cm2 [interquartile range (IQR) −58.7, TGF-beta inhibitor review 14.2 cm2] in the GH group, vs. 12.6 cm2 (IQR −11.3, 24.5 cm2) in the placebo group (P=0.025) and corresponding percentage changes in VAT were −11% in the GH group and +6% in the placebo group, giving a treatment effect of a reduction in VAT of approximately 17%. Trunk fat mass changed by −548 g (IQR −1098, 36 g) in the GH group, vs. 353 g (IQR −167, 572 g) in the placebo group (P=0.007), which corresponded to a trunk fat reduction of 9% in the GH group and an increase of 6% in the placebo group, giving a treatment effect of a reduction in trunk fat of approximately 15%. Limb selleck chemicals fat mass was unchanged in the GH group (92 g; IQR −268, 298 g) and in the placebo group (55 g; IQR −320, 297 g) (P=0.647). The change in

the percentage of limb fat differed significantly between the GH group, at 1.7% (IQR 0.8, 3.5%), and the placebo group, at −0.6% (IQR 2.8, 0.5%) (P=0.001), as did the change in lean mass, at 1428 g (IQR 134, 2749 g) for the GH group vs. 182 g (IQR −676, 877 g) for the placebo group (P=0.004). Measures of subcutaneous fat at the abdomen and femur, waist and hip circumferences, and waist:hip ratio did not differ significantly between groups. Approximately half of the patients included in the study were diagnosed with HALS, and the remainder were diagnosed as not having HALS. Study

Rucaparib treatment was stratified according to the presence of HALS. In the resultant four groups, mean differences in VAT, trunk fat mass and limb fat mass were: in the GH with HALS group, −30.4 cm2 [standard deviation (SD) 44.3 cm2], −665 g (SD 1422 g) and −88 g (SD 635 g); in the GH without HALS group, −5.4 cm2 (SD 37.5 cm2), −551 g (SD 687 g) and −23 g (SD 468 g); in the placebo with HALS group, 20.9 cm2 (SD 37.3 cm2), 490 g (SD 707 g) and −23 g (SD 358 g); and in the placebo without HALS group, −2.6 cm2 (SD 22.2 cm2), −44 g (SD 710 g) and −41 g (SD 680 g). VAT (P=0.019) and trunk fat mass (P=0.047) were significantly reduced in the GH with HALS group compared with the placebo with HALS group, whereas limb fat mass remained unchanged (P=0.99).